A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Recruiting · Phase 3 · NCT07218380
Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
At a glance
- Research payments reported, 2025
- $55,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 450
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Vepugratinib (drug), Placebo (other), EV (drug), Pembrolizumab (drug)
- Dates
- Started 2025-12-12; completion 2033-05
- Results posted
- Not yet
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
From ClinicalTrials.gov, last updated 2026-10-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $55,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- World Research Link $55,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.